Research and Markets (http://www.researchandmarkets.com/research/49zp6c/global_erectile)
has announced the addition of the "Global
Erectile Dysfunction Epidemiology and Patient Flow Analysis - 2012"
report to their offering.
Fore Pharma announced the results of its Erectile Dysfunction patient
population study in a new report Global Erectile Dysfunction
Epidemiology and Patient Flow Analysis - 2012'. The report provides
insights into Erectile Dysfunction epidemiology, Erectile Dysfunction
diagnosed patients, and Erectile Dysfunction treatment rate for top
seven pharmaceutical markets. The study measures key indcators such as
prevalence of Erectile Dysfunction derived from epidemiological
analysis, percentage of patients diagnosed with Erectile Dysfunction,
and percentage of patients treated with Erectile Dysfunction therapy.
The study helps executives estimate Erectile Dysfunction market
potential, assess unmet need, develop drug forecasting models, and build
population-based health management frameworks. The information presented
in this study is used to evaluate market opportunities, effectively
identify target patient population, and align marketing decisions.
The report provides estimates and forecasts of Erectile Dysfunction
prevalence, Erectile Dysfunction diagnosis rate, and Erectile
Dysfunction treatment rate for the period 2012-2019. The information is
presented by leading geographies including the US, Germany, France,
Spain, Italy, UK, and Japan. The study design is based on collection and
interpretation of data from registries, scientific journals and
literatures, government databases and other secondary sources.
Key Features of the Report:
- Erectile Dysfunction: Disease Definition
- Erectile Dysfunction Patient Flow
- Erectile Dysfunction Prevalence
- Erectile Dysfunction Diagnosed Patients
- Erectile Dysfunction Treated Patients
For more information visit http://www.researchandmarkets.com/research/49zp6c/global_erectile
[ Back To NFVZone's Homepage ]